文献速递头颈部肿瘤放疗姑息放疗与转移瘤

寡转移性头颈癌:哪些患者能从所有肿瘤部位的根治性局部治疗中获益?

Oligometastatic head and neck cancer: Which patients benefit from radical local treatment of all tumour sites?
PubMed 文献 · Radiat Oncol · 2021-03-31

本研究纳入40例新诊断的寡转移性头颈癌患者,均接受所有肿瘤部位的根治性局部治疗,中位总生存期为23.0个月,2年、3年、4年和5年生存率分别为48%、37%、24%和16%。多因素分析显示,ECOG状态较好、无骨和脑转移以及总肿瘤体积较低与生存改善显著相关。

要点

  • 根治性局部治疗包括放疗(90%)、手术(25%)和射频消融(3%)。
  • 中位总生存期23.0个月,5年生存率16%。
  • ECOG状态好、无骨/脑转移、总肿瘤体积低者生存更优。

核心结论

  • 寡转移性头颈癌的根治性局部治疗显示出有希望的结果,需要进一步研究。
  • ECOG状态较好、无骨和脑转移以及总肿瘤体积较低的患者被确定为根治性局部治疗的最佳候选者。

研究设计与样本

  • 单中心研究纳入40例新诊断的寡转移性头颈癌患者,2008年2月14日至2018年8月24日接受所有肿瘤部位的根治性局部治疗。
  • 主要终点为总生存期,次要终点包括新发远处转移时间、局部控制及预后因素分析。
  • 在基线影像上对所有肿瘤部位进行分割以评估总肿瘤体积对生存的影响。

主要发现

  • 根治性局部治疗包括放疗(90%)、手术(25%)和射频消融(3%)。
  • 从首次诊断寡转移性疾病起,中位总生存期为23.0个月,2年生存率48%,3年生存率37%,4年生存率24%,5年生存率16%。
  • 新发远处转移的中位时间为11.6个月,3年随访后无新转移生存呈尾部模式(治疗后3、4和5年均为22%)。
  • 多因素分析中,ECOG状态较好、无骨和脑转移以及总肿瘤体积较低与生存改善显著相关,而转移数目和受累器官部位数则无显著关联。

临床怎么用

  • 对于ECOG状态较好、无骨和脑转移且总肿瘤体积较低的寡转移性头颈癌患者,可考虑根治性局部治疗所有肿瘤部位。
  • 未来前瞻性试验应基于ECOG状态、骨/脑转移状态和总肿瘤体积进行患者选择。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a large lack of evidence for optimal treatment in oligometastatic head and neck cancer and it is especially unclear which patients benefit from radical local treatment of all tumour sites. METHODS: 40 patients with newly diagnosed oligometastatic head and neck cancer received radical local treatment of all tumour sites from 14.02.2008 to 24.08.2018. Primary endpoint was overall survival. Time to occurrence of new distant metastases and local control were evaluated as secondary endpoints as well as prognostic factors in univariate und multivariate Cox's regression analysis. To investigate the impact of total tumour volume on survival, all tumour sites were segmented on baseline imaging. RESULTS: Radical local treatment included radiotherapy in 90% of patients, surgery in 25% and radiofrequency ablation in 3%. Median overall survival from first diagnosis of oligometastatic disease was 23.0 months, 2-year survival was 48%, 3-year survival was 37%, 4-year survival was 24% and 5-year survival was 16%. Median time to occurrence of new distant metastases was 11.6 months with freedom from new metastases showing a tail pattern after 3 years of follow-up (22% at 3, 4- and 5-years post-treatment). In multivariate analysis, better ECOG status, absence of bone and brain metastases and lower total tumour volume were significantly associated with improved survival, whereas the number of metastases and involved organ sites was not. CONCLUSIONS: Radical local treatment in oligometastatic head and neck cancer shows promising outcomes and needs to be further pursued. Patients with good performance status, absence of brain and bone metastases and low total tumour volume were identified as optimal candidates for radical local treatment in oligometastatic head and neck cancer and should be considered for selection in future prospective trials.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Weissmann T, Höfler D, Hecht M, et al. Oligometastatic head and neck cancer: Which patients benefit from radical local treatment of all tumour sites? Radiat Oncol. 2021. PMID: 33789725. doi:10.1186/s13014-021-01790-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。